Document Type
Article
Publication Date
2-2-2021
Keywords
JMG
JAX Source
Clin Transl Immunol 2021 Feb 2; 10(2):e1246
Volume
10
Issue
2
First Page
1246
Last Page
1246
ISSN
2050-0068
PMID
33552509
DOI
https://doi.org/10.1002/cti2.1246
Grant
CA034196
Abstract
Objectives: With a rapidly growing list of candidate immune-based cancer therapeutics, there is a critical need to generate highly reliable animal models to preclinically evaluate the efficacy of emerging immune-based therapies, facilitating successful clinical translation. Our aim was to design and validate a novel
Methods: Tumor xenografts are established rapidly in the greater omentum of globally immunodeficient NOD-
Results: The tumors progress rapidly and disseminate in the mice unless patient-derived tumor-specific T cells are introduced. An initial T cell-mediated tumor arrest is later followed by a tumor escape, which correlates with the upregulation of the checkpoint molecules programmed cell death-1 (PD-1) and lymphocyte-activation gene 3 (LAG3) on T cells. Treatment with immune-based therapies that target these checkpoints, such as anti-PD-1 antibody (nivolumab) or interleukin-12 (IL-12), prevented or delayed the tumor escape. Furthermore, IL-12 treatment suppressed PD-1 and LAG3 upregulation on T cells.
Conclusion: Together, these results validate the X-mouse model and establish its potential to preclinically evaluate the therapeutic efficacy of immune-based therapies.
Recommended Citation
Shenoy G,
Greene C,
Bhatta M,
Baroja M,
Loyall J,
Balu-Iyer S,
Kelleher R,
Carreno B,
Linette G,
Shultz LD,
Bankert R.
Preclinical evaluation of cancer immune therapy using patient-derived tumor antigen-specific T cells in a novel xenograft platform. Clin Transl Immunol 2021 Feb 2; 10(2):e1246
Comments
This is an open access article under the terms of the Creative Commons Attribution License.